Document Type : Research Paper


Department of Chemistry, College of Education for Pure Science , University Of Anbar, Ramadi, Iraq;


Thyroid dysfunctions (TDs) are the most common endocrine diseases, especially in women. Phrase "thyroid dysfunction" refers to a variety of diseases affecting the thyroid gland and its hormones. This study aims to compare serum neudesin levels and lipid profiles between people with and without thyroid dysfunction. Study involved 56 TDs patients from a medical laboratory and 28 healthy controls (HCs). Neudesin concentration in serum was assessed using an enzyme-linked immunosorbent test (ELISA), whilst triglycerides (TGs), total cholesterol (T. Cho), High-density lipoprotein cholesterol (HDL-C) and total cholesterol levels were measured using enzyme colorimetry. Serum level of  neudesin was lower in thyroid dysfunction patients than in HCs (P< 0.000l), neudesin has an important negative correlation with TGs, HDL, and very low-density lipoprotein (VLDL) (mg/dL) (P< 0.000l), while it showed a positive correlation with low-density lipoprotein (LDL) (mg/dL) (P < 0.000l). Studied parameters showed of the areas under the receiver operating characteristic (AUROC) curve hypothyroidism and hyperthyroidism, respectively: Neudesin (0.8017 and 0.9043 ng/mL), HDL (0.677 and 0.5708 mg/dL), triiodothyronine (T3) (0.8578 and 1 nmol/L), thyroxine (T4) (0.9872 and 1 nmol/L), thyroid-stimulating hormone (TSH) (0.9847 and 0.757 mIU/mL), T. Cho. (0.909 and 0.6645 mg/dL), TGs (0.944 and 0.669 mg/dL), VLDL (0.942 and 0.669 mg/dL), and LDL (0.872 and 0.7526 mg/dL). Present study found serum levels of neudesin showed a negative correlation with T.Cho, and LDL in hyperthyroidism patients while showing a negative correlation with triglycerides and VLDL in hypothyroidism patients.


Main Subjects

[1]   H. Q. Wang, W. Di Zhang, B. Yuan, and J. B. Zhang, (2021) “Advances in the regulation of mammalian follicle-stimulating hormone secretion,” Animals, vol. 11, no. 4
[2]   D. Horgan et al., (2022) “Tackling Thyroid Cancer in Europe—The Challenges and Opportunities,” Healthc., vol. 10, no. 9, pp. 1–13.
[3]   L. Chaker, A. C. Bianco, J. Jonklaas, and R. P. Peeters, (2017) “Hypothyroidism,” Lancet, vol. 390, no. 10101, pp. 1550–1562.
[4]   J. R. Stockigt, “Free thyroid hormone measurement: A critical appraisal, (2001)” Endocrinol. Metab. Clin. North Am., vol. 30, no. 2, pp. 265–289.
[5]   R. Wang, J. C. Nelson, R. M. Weiss, and R. B. Wilcox, (2000) “Accuracy of free thyroxine measurements across natural ranges of thyroxine binding to serum proteins,” Thyroid, vol. 10, no. 1, pp. 31–39.
[6]   M. S. Byerly et al., (2013) “Identification of hypothalamic neuron-derived neurotrophic factor as a novel factor modulating appetite,” Am. J. Physiol. - Regul. Integr. Comp. Physiol., vol. 304, no. 12, pp. 1085–1095.
[7]   H. Y. Yasar, M. Demirpence, A. Colak, M. Zeytinli, E. Yasar, and A. Taylan, (2022) “Serum neudesin levels in patients with polycystic ovary syndrome,” Ginekol. Pol., vol. 93, no. 7, pp. 525–530.
[8]   A. Polkowska, I. E. Pasierowska, M. Pasławska, E. Pawluczuk, and A. Bossowski, (2019) “Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes,” Biomed Res. Int., vol. 2019, p. 6.
[9]   E. Ç. Eren, S. Kaya, and D. Argun, (2022) “The assessment of maternal and umbilical cord neudesin levels in pregnancies with gestational diabetes mellitus,” J. Obstet. Gynaecol. (Lahore)., vol. 42, no. 7, pp. 2941–2945.
[10] G. J. Canaris, N. R. Manowitz, G. Mayor, and E. C. Ridgway, (2000) “The colorado thyroid disease prevalence study,” Arch. Intern. Med., vol. 160, no. 4, pp. 526–534.
[11] L. H. Duntas, (2002) “Thyroid disease and lipids,” Thyroid, vol. 12, no. 4, pp. 287–293.
[12] D. V. Kumar, D. S. L. Mathur, and D. R. K. Tuteja, (2019) “Effects of Thyroid Dysfunction on Lipid Profile,” Int. J. Med. Biomed. Stud., vol. 3, no. 6, pp. 76–84.
[13] S. F. Tuleab Alaaraji, (2019) “Exploration of the Relationship between Interleukins 17, 37 and 38 with Vitamin E in Iraqi Men with CHB,” J. Phys. Conf. Ser., vol. 1294, no. 5.
[14] K. F. Al-Rawi et al., (2022) “Relationship Between IL-2, IL-17 Concentrations, and Serum Creatinine Levels in Men with Chronic Kidney Diseases,” Reports Biochem. Mol. Biol., vol. 10, no. 4, pp. 664–674.
[15] T. V. T. Tran, C. M. Kitahara, F. de Vathaire, M. C. Boutron-Ruault, and N. Journy, (2020) “Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis,” Endocr. Relat. Cancer, vol. 27, no. 4, pp. 245–249.
[16] H. Münzberg and L. Receptor, (2010) “Leptin-Signaling Pathways and Leptin Resistance Leptin Action in the Central Nervous System,” vol. 63, pp. 123–132.
[17] S. A. W. A.-S. Abdul Hadeel, (2022) “Neudesin Levels in Patients with Thyroidism,” Egypt. J. Hosp. Med., vol. 89, no. October, pp. 7809–7813.
[18] G. Bozkaya, O. Fenercioglu, İ. Demir, A. Guler, B. Aslanipour, and M. Calan, (2020) “Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome,” Gynecol. Endocrinol., vol. 36, no. 10, pp. 849–853.
[19] E. Vergani, C. Bruno, C. Cipolla, D. Currò, and A. Mancini, (2022) “Plasma Levels of Neudesin and Glucose Metabolism in Obese and Overweight Children,” Front. Endocrinol. (Lausanne)., vol. 13, no. July, pp. 1–7.
[20] T. Friis and L. R. Pedersen, (1987) “Serum lipids in hyper- and hypothyroidism before and after treatment,” Clin. Chim. Acta, vol. 162, no. 2, pp. 155–163.